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Microtubule Alterations and Mutations
Induced by Desoxyepothilone B:
Implications for Drug-Target Interactions
epothilones which were originally identified in myxo-
bacterium S. cellulosum and are structurally distinct
from the taxanes. Bollag et al. [7] isolated epothilone
A and B which belong to the 16-membered macrolide
antibiotic family of compounds. In vitro, epothilones in-
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bules and can stabilize preformed microtubules againstRandwick, New South Wales, 2031
2 Australian Proteome Analysis Facility depolymerization [7, 8]. Mutational and pharmacophore
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Sydney, New South Wales, 2109 taxel and the epothilones [9–12], and indeed these com-
pounds competitively inhibit [3H]-paclitaxel binding to3 Faculty of Pharmacy
University of Sydney microtubules [7, 8]. As with paclitaxel, epothilones arrest
cells at the G2M transition of the cell cycle leading toSydney, New South Wales, 2006
Australia cell death; however, unlike paclitaxel, the epothilones
retain cytotoxicity in P-glycoprotein-expressing multi-
drug-resistant (MDR) cells [7, 8, 12, 13]. In vivo, EpoA
and EpoB showed only moderate antitumor activity dueSummary
to a narrow therapeutic window [14, 15]; however, phase I
clinical trials of EpoB, and a synthetic analog, BMS-Epothilones, like paclitaxel, bind to -tubulin and sta-
247550, are encouraging [16]. A recently developedbilize microtubules. We selected a series of four leuke-
EpoB analog, Z-12,13-desoxyepothilone B (dEpoB), hasmia sublines that display increasing levels of resis-
shown very promising in vivo activity [13, 14, 17]. Whiletance to the epothilone analog desoxyepothilone B
less potent than EpoB in vitro, a comparative study(dEpoB). The dEpoB cells selected in 30–140 nM were
showed dEpoB to have the least cross-resistance com-15-fold cross-resistant to paclitaxel, while 300 nM
pared to epothilones A, B, and dEpoA in numerous drug-selected cells were 467-fold resistant to this agent.
resistant cancer cell lines [13]. dEpoB also showed theThe dEpoB-selected cells are hypersensitive to micro-
greatest therapeutic effect in xenograft models, includ-tubule destabilizing agents, and express increased
ing mice bearing doxorubicin-resistant human mam-levels of class III -tubulin and MAP4. A novel class I
mary adenocarcinoma xenografts and MDR human-tubulin mutation, A231T, that affects microtubule
lymphoblastic T cell leukemia (CCRF-CEM/paclitaxel)stability but does not alter paclitaxel binding, was iden-
[13, 14]. In a more extensive study, dEpoB showed variabletified. The 300 nM selected cells acquired a second
efficacy compared to paclitaxel in a panel of human xeno-mutation, Q292E, situated near the M loop of class I
grafts; however, in all drug-resistant tumors analyzed,-tubulin. These cells fail to undergo drug-induced
dEpoB showed the greatest therapeutic effect [17].tubulin polymerization due to dramatically reduced
To enhance understanding of the drug-target interac-drug binding. The dEpoB-resistant leukemia cells pro-
tions of dEpoB, and to identify resistance mechanism(s)vide novel insights into microtubule dynamics and, in
to aid in future drug design of related agents, we haveparticular, drug-target interactions.
selected a series of human T cell acute lymphoblas-
tic leukemia (ALL) cells, CCRF-CEM, for resistance to
Introduction dEpoB. Stepwise selection in dEpoB resulted in four
cell lines with increasing resistance to the selecting
Natural product antimitotic drugs targeting the tubulin/ agent that display cross-resistance to microtubule-sta-
microtubule system are important in the treatment of a bilizing agents and hypersensitivity to microtubule-
range of haematologic and solid cancers. One of these destabilizing agents. The resistant cells initially acquired
agents, paclitaxel (Taxol), is used in the treatment of a a mutation in -tubulin that resulted in reduced microtu-
variety of tumor types including lung, ovarian, and breast bule stability counteracting the effects of microtubule
cancer [1]. Paclitaxel induces its effect through its ability stabilizing agents. In the highly resistant subline, the
to bind to the tubulin dimer at the core of the microtubule cells acquired a second mutation that resulted in re-
structure [2] and disrupts the tubulin-microtubule equi- duced drug binding. This study provides novel insights
librium by stabilizing the polymerized form [3]. Agents into microtubule stability and, in particular, drug-target
such as paclitaxel are believed to exert their cytotoxic interactions.
effect by interfering with the function of the mitotic spin-
dle, blocking cells at the metaphase/anaphase junction
of mitosis [4]. Results
Recently, new agents with similar microtubule stabiliz-
ing effects to paclitaxel have been identified [5, 6]. Resistance Profiles of dEpoB-Selected
Among the most promising class of new agents are the Leukemia Cells
Selection of CCRF-CEM leukemia cells with increasing
concentrations of dEpoB resulted in the derivation of*Correspondence: m.kavallaris@unsw.edu.au
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play cross-resistance to paclitaxel; however, the extent
of resistance in the dEpoB300 cells is far greater than
in any of the other cell lines and is also greater than the
fold resistance to the selecting agent, dEpoB (Figure
1B; Table 1). Resistance to the related drug, EpoB, was
less than that to the selecting agent (Table 1). Analysis
of growth rates showed that the dEpoB-resistant cells
have a slightly reduced doubling time (CEM, 22.3 hr;
dEpoB30, 18.6 hr; dEpoB60, 17.6 hr; dEpoB140, 20.5
hr; dEpoB300, 20.4 hr; data not shown), and none of the
cell lines are dependent on dEpoB for growth.
Interestingly, dEpoB-resistant cell lines are hypersen-
sitive to vinca alkaloids which destabilize microtubules
(Table 1). The dEpoB30 cell line shows the broadest
sensitivity to vinca alkaloids, being hypersensitive to
vincristine, vinblastine, and vinorelbine. The dEpoB300
cells are hypersensitive to vinblastine and vinflunine with
a trend toward hypersensitivity to vinorelbine, while the
dEpoB60 cells are hypersensitive only to vinblastine. No
significant cross-resistance was observed to the DNA
binding agent doxorubicin in any of the dEpoB-selected
sublines.
Resistance Is Not Due to Increased MDR1
or MRP1 Expression
P-glycoprotein (encoded by the MDR1 gene) and the
multidrug-resistance associated protein 1 (encoded by
the MRP1 gene) are membrane transporters associated
with the MDR phenotype. Semiquantitative competitive
RT-PCR showed that expression of the MDR1 and MRP1
genes were not upregulated in the dEpoB-resistant cellFigure 1. Resistance Profiles with the Selecting Agent, dEpoB, and
Paclitaxel lines (Supplementary Figures S1A and S1B at http://
(A) The dEpoB30, dEpoB60, dEpoB140, and dEpoB300 cells display www.chembiol.com/cgi/content/full/10/7/597/DC1). To
increasing resistance to dEpoB, respectively. determine whether decreased drug accumulation was
(B) The dEpoB30, dEpoB60, and dEpoB140 cells all show similar contributing to resistance, accumulation of [3H]-pacli-
levels of cross-resistance to paclitaxel. The dEpoB300 cells show taxel was analyzed. No reduction in [3H]-paclitaxel accu-
much higher cross-resistance to this drug. Cytotoxicity assays were
mulation was observed in the dEpoB-resistant cellsperformed on the CEM (open circles), dEpoB30 (closed circles),
(Supplementary Figure S1C at http://www.chembiol.dEpoB60 (closed squares), dEpoB140 (closed triangles), and
dEpoB300 (closed diamonds) cell lines as described in Experimental com/cgi/content/full/10/7/597/DC1). These results sug-
Procedures. All assays were run with four replicates at eight concen- gest that the resistance profile of the dEpoB cells is not
trations of drug. Bars, SE of three individual experiments. attributable to decreased drug accumulation.
Altered Tubulin and MAP4 Expressionfour sublines, designated CEM/dEpoB30, CEM/dEpoB60,
CEM/dEpoB140, and CEM/dEpoB300. The resultant in dEpoB-Resistant Cells
Previous studies have identified altered expression ofsublines are 21-, 60-, 173-, and 307-fold resistant to
dEpoB respectively, compared to parental CEM cells specific tubulin isotypes and microtubule-associated
proteins (MAPs) in association with antimicrotubule(Figure 1A; Table 1). The dEpoB-resistant cells also dis-
Table 1. Resistance of CEM/dEpoB-Selected Cells
Relative Resistancea
Cell Line dEpoB EpoB Ptx VCR VLB VNFL VNRL COLC DOX
dEpoB30 21** NT 16** 0.6* 0.28* 0.82 0.43* 0.78 1.4
dEpoB60 60** NT 26** 1.5 0.58* 0.73 0.94 0.88 1.8
dEpoB140 173** 12** 7* 2.3 0.79 0.86 1.31 0.88 2.2
dEpoB300 307** 77** 467** 1.3 0.25* 0.52* 0.59 0.85 1.1
* p  0.05; **p  0.005. The IC50 values (Log M)  SE of the parent CEM cells are as follows: dEpoB, 1.07  109  0.055; EpoB, 4.66 
1010  0.023; Ptx, 4.50  1012  0.048; VCR, 2.26  1010  0.060; VLB, 4.29  109  0.075; VNFL, 3.16  108  0.005; VNRL, 2.49 
109  0.067; COLC, 3.66  109  0.064; and DOX, 1.26  109  0.501.
Abbreviations: dEpoB, desoxyepothilone B; EpoB, epothilone B; Ptx, paclitaxel; VCR, vincristine; VLB, vinblastine; VNFL, vinflunine; VNRL,
vinorelbine; COLC, colchicine; DOX, doxorubicin; and NT, not tested.
a Determined by dividing the IC50 for the resistant cell line by the IC50 of the parent (CEM) cell line.
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Figure 2. Altered Protein Expression of Tu-
bulin and MAP4
Total cellular protein (10 g) from CEM (lane 1),
dEpoB30 (lane 2), dEpoB60 (lane 3), dEpoB140
(lane 4), and dEpoB300 (lane 5) was sepa-
rated on 4%–15% SDS-PAGE, electrotrans-
ferred to nitrocellulose, and immunodetected
with antibodies against class I -tubulin (A);
class II -tubulin (B); class III -tubulin (C);
and MAP4 (D). Membranes were stripped and
reprobed with actin. Inset panel above each
graph is a representative blot of four indepen-
dent experiments. The relative expression of
each protein was determined by dividing the
densitometric value of the test protein by that
of the actin control. Bars,SE of four experi-
ments; *p  0.05; **p  0.005.
drug resistance [18–20]. To analyze the protein expres- dEpoB, drug was introduced to the cell lysis buffer. The
parental cells show significant increases in polymerizedsion in dEpoB-resistant cells, Western blots were per-
formed (Figure 2). All dEpoB-resistant cells have slightly tubulin with 4g/ml dEpoB (Figure 3). At 4 g/ml dEpoB,
the proportional increase in polymerized tubulin in thereduced expression of class I -tubulin (Figure 2A), and
class II -tubulin is reduced only in the dEpoB300 cells dEpoB30-140 cells is similar to the parental CEM cells.
It must be noted, however, that as intrinsic levels were(Figure 2B). In contrast, class III -tubulin, a protein
previously shown to be upregulated in cells resistant to lower in all the resistant cells, the overall amounts of
polymerized tubulin still remained less than in the CEMmicrotubule-stabilizing agents, and downregulated in
cells resistant to microtubule-destabilizing drugs (re- cells. In contrast, addition of dEpoB to the dEpoB300
cells failed to induce tubulin polymerization.viewed in [19, 20]), showed increased expression in all
dEpoB-resistant cells. dEpoB30 and dEpoB300 cells
had the greatest increase in this isotype (approximately dEpoB300 Cells Have Impaired Paclitaxel Binding
To determine whether the lack of drug-induced tubulin3-fold) compared to the parental CCRF-CEM cells (Fig-
ure 2C). Interestingly the dEpoB30 and dEpoB300 sub- polymerization is due directly to reduced drug binding
to microtubules, cells were treated with [3H]-paclitaxellines also displayed the broadest hypersensitivity to
vinca alkaloids (Table 1). No significant change in total for 1 hr prior to separation of soluble and polymerized
fractions of tubulin. The total [3H]-paclitaxel was deter--tubulin was observed (data not shown). Modification
of MAP4 expression can lead to altered efficacy of anti- mined relative to the total protein in each polymerized
fraction (Figure 4). The dEpoB30-140 cells bound themicrotubule agents [21, 22], and expression of this MAP
was increased approximately 2-fold in all dEpoB-resis- same amount of [3H]-paclitaxel as the parental CEM
cells. In contrast, dEpoB300 cells bound less than halftant cells (Figure 2D).
that amount compared to CEM cells (p  0.0001). Thus,
the dEpoB300 cells have greatly reduced binding effi-dEpoB-Resistant Cells Have Reduced Intrinsic
and Drug-Induced Polymerized Tubulin ciency for [3H]-paclitaxel compared to the drug-sensitive
parental cells.To assess the capacity of tubulin to form stable microtu-
bules in the resistant sublines, soluble and polymerized
pools of tubulin were separated from cell lysates and dEpoB-Resistant Cells Have Mutations in HM40
(Class I) -Tubulinthe relative proportions determined by Western blotting.
The dEpoB-resistant cells have greatly reduced amounts To determine if reduced polymerized tubulin levels were
due to mutations in tubulin, the predominant -tubulinof polymerized tubulin compared to the CEM cells (Fig-
ure 3). The percentage of polymerized tubulin is 27.5% isotype gene, HM40 (encodes class I -tubulin), was
sequenced in the dEpoB-selected cells. A heterozygousin the parental CEM cells, and 17.5%, 13.4%, 9.3%,
and 6.9% in the dEpoB30, dEpoB60, dEpoB140, and point mutation at nucleotide 691 (GCC→ACC), resulting
in an alanine to threonine substitution at amino acid 231dEpoB300 cells respectively (Figure 3B). Thus, the rela-
tive levels of polymerized tubulin decreases as the ex- was observed in all dEpoB-resistant cell lines. A second
heterozygous point mutation at nucleotide 874 (CAG→tent of dEpoB resistance increases. To determine if the
tubulin in these cells could be induced to polymerize by GAG), substituting a glutamine to glutamic acid at amino
Chemistry & Biology
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Figure 4. dEpoB-Resistant Cells Display Reduced [3H]-Paclitaxel
Binding
Cells were incubated in the presence of [3H]-paclitaxel for 60 min
prior to separating the soluble and polymerized pools of tubulin as
described in Experimental Procedures. The amount of [3H]-pacli-
taxel in the polymerized fraction was determined and the results
expressed as pmol paclitaxel/mg protein. Analysis of variance was
calculated for each dEpoB value compared to the parental CEM
cells. Bars, SE.
(data not shown). Analysis of the tryptic peptide spec-
trum of class I -tubulin spot 2 identified one peptide of
different mass in the parental CEM cells and the dEpoB-
resistant cells (data not shown). The ion at 908.32 in the
CEM cells corresponds to the H3 tryptic peptide of
Figure 3. Decreased Polymerized Tubulin and Reduced Drug- amino acids 217–241. In the dEpoB140 cells, this
Induced Polymerization in dEpoB-Resistant Cells peptide is replaced by a H3 ion at 918.31, a relative
(A) Soluble and polymerized pools of tubulin were separated in the increase of 30 Da. Upon tandem MS and amino acid
absence or presence of 4 g/ml dEpoB in the lysis buffer, and
sequence analysis, 14 amino acids could be called andrelative amounts determined by Western blotting with a mAb to total
the sequence of these two peptides was found to be-tubulin.
HLVSATMSGVTTCL and HLVSTTMSGVTTCL respec-(B) The percent polymerized tubulin was calculated by dividing the
polymerized fraction (P) by the total polymerized and soluble frac- tively (Figures 5Aii and 5Aiii). Thus, the increase in 30
tions (P  S), and values are SE for three individual experiments. Da is due to the substitution of an alanine for a threonine
S, soluble; P, polymerized. Analysis of variance was calculated for at position 231 in the dEpoB-resistant cells. The point
each dEpoB value compared to the parental CEM cells. Bars, SE.
mutation at nucleotide 691 identified in the HM40 gene is
therefore translated and expressed at the protein level.
Similarly, the Q292E mutation observed in the HM40
acid 292 was found in the dEpoB140 and dEpoB300
gene sequence is expressed at the protein level in the
cells. Interestingly, the wild-type base at this position
dEpoB300 cells (Figure 5B). In this case, the MALDI-
in the dEpoB140 cells predominated over the mutant,
TOF spectra showed a 1660.99 Da peptide in the CEM
while in the dEpoB300 cells, the mutant sequence pre-
cells, substituted by a peptide at 1661.98 Da in the
dominated (data not shown), indicating that this muta-
dEpoB300 cells. ESI-TOF MS/MS on this peptide identi-
tion occurred in the late stages of the dEpoB140 selec-
fied the sequence as TVPELTQQVFDAK and TVPELT
tion, and gave a selective advantage over the wild-type
QEVFDAK (amino acids 285–297) in the CEM and
in the dEpoB300 selection.
dEpoB300 cells respectively, and thus the mutation of
glutamine to glutamic acid is also present at the protein
level (Figure 5Biii). Expression of the Q292E mutationClass I -Tubulin Mutations Are Expressed
at the Protein Level was only observed at the protein level in the dEpoB300
cells. This amino acid substitution results in the gain ofTo ensure that the mutations identified in the HM40 gene
are translated and expressed at the protein level, cellular an acidic residue, hence decreasing the isoelectric point
of the protein causing it to migrate to a more acidicproteins were separated by 2D-PAGE and tubulin tryptic
peptides analyzed by mass spectrometry (MS) (Figures region in the 2D gel. The mutated polypeptide is now
migrating directly underneath the class II -tubulin spot5A and 5B). Spots 1 and 3 were identified by MALDI-TOF
MS peptide mass fingerprinting and Western blotting as 3 (Figure 5Bi). Spot 3 was analyzed by peptide mass
fingerprinting and MS/MS to confirm that the peptideclass II -tubulin, and spots 2 and 4 as class I -tubulin
Microtubule Alterations and Drug Action
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Figure 5. Mutations in Class I -Tubulin Are Expressed at the Protein Level
(Ai) Cellular proteins from CEM and dEpoB140 cells were separated by 2D-PAGE and stained with SYPRO Ruby. Tubulin spots were excised
from the gel, in-gel trypsin digested, and resulting peptides analyzed by MALDI-TOF MS. Spots 1 and 3 were identified as class II -tubulin
and spots 2 and 4 as class I -tubulin. Spectra were compared for each protein in the CEM, and dEpoB140 cells and peptides differing in
mass were selected for tandem mass spectrometry (MS/MS).
(Aii) ESI-TOF MS/MS spectrum of peptide with mass 2634.79 Da (ion 908.323) from the CEM cells.
(Aiii) ESI-TOF MS/MS spectrum of peptide with mass 2664.69 Da (ion 918.313) from the dEpoB140 cells.
(Bi) Cellular proteins from CEM and dEpoB300 cells were separated by 2D-PAGE and stained with SYPRO Ruby. Tubulin spots were excised
from the gel, in-gel trypsin digested, and resulting peptides analyzed by MALDI-TOF MS. Spots 1 and 3 were identified as class II -tubulin
and spots 2, 4, and 5 as class I -tubulin. Spectra were compared for each protein in the CEM and dEpoB300 cells, and peptides differing
in mass were selected for tandem mass spectrometry (MS/MS).
(Bii) ESI-TOF MS/MS spectrum of peptide at mass 1660.99 Da from the CEM cells.
(Biii) ESI-TOF MS/MS spectrum of peptide at mass 1661.98 Da from the dEpoB300 cells. ESI-TOF MS/MS data was manually analyzed to
determine the amino acid sequence of selected peptides.
shift and Q292E mutation was seen only in the lower, S9–S10 loops and bounded by helices H6 and H7. This
region of -tubulin is thought to play an important role inclass I -tubulin spot (Figure 5Bi, dEpoB300 spot 5). In
addition to the mutations identified, 2D-PAGE analysis the formation of lateral contacts between protofilaments
[24]. Molecular modeling studies have positioned theshows the loss of a class II -tubulin protein spot in
the dEpoB300 cells (Figure 5Bi, spot 1). This finding A231T and Q292E mutations in -tubulin. The novel A231T
mutation resides on helix 7 (H7) of -tubulin (Figure 6),corresponds to the reduced class II-tubulin expression
observed in these cells by Western blotting (Figure 2B). which has previously been defined as part of the pacli-
taxel binding site [25] and is also a region implicated in
controlling the conformation of the tubulin molecule [26,Mutations in -Tubulin Map to H7 in the Drug
Binding Site and H9 Near the M Loop 27]. The second -tubulin mutation, Q292E, is located
on H9 near the M loop (Figure 6), a region important inAn increasingly well-resolved model for the / tubulin
dimer has been obtained through the application of elec- the interactions between protofilaments.
tron crystallography to zinc induced paclitaxel-tubulin
sheets [23]. A ribboned diagram for the -tubulin mono- Discussion
mer as deposited in the Protein Data Bank (PDB: 1JFF)
is illustrated in Figure 6, which shows paclitaxel binding The EpoB analog Z-12,13-desoxyepothilone B (dEpoB)
displays promising in vivo activity, and only low-levelin a very large binding site lying between the M and
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Figure 6. Modeling of the A231T and Q292E
Mutations in -Tubulin
The molecular structure of the /-tubulin
heterodimer has recently been determined
(PDB: 1JFF). This figure shows paclitaxel
binding in a very large binding site lying be-
tween the M and S9–S10 loops and bounded
by helices H6 and H7. The A231T mutation
identified in all the dEpoB-resistant cell lines
is located on H7 within the paclitaxel binding
site. The Q292E mutation identified in the
dEpoB300 cells is situated on H9 near the
edge of the M loop, a region implicated in
lateral contacts of protofilaments and pacli-
taxel binding.
resistance to dEpoB has previously been achieved in some ability to polymerize. However, the reduced initial
polymer mass would render fewer microtubules avail-culture [17]. An important benefit of the epothilones over
existing antimicrotubule agents such as paclitaxel is able for drug binding and hence reduce drug efficacy.
In contrast, dEpoB could not induce tubulin polymeriza-primarily due to the ability of these agents to retain
cytotoxicity against MDR cells [7, 8]. This study de- tion in the dEpoB300 cells.
According to the “T-paclitaxel conformation bound toscribes the selection and characterization of dEpoB-
resistant human ALL cells (CCRF-CEM) in which re- -tubulin model” proposed by Snyder et al. [30], the
novel human class I -tubulin A231T mutation identifiedduced drug accumulation and the MDR-phenotype is
not involved in the resistance phenotype. The major in the dEpoB-resistant CEM cells lies in the highly hy-
drophobic paclitaxel binding region of -tubulin. Thismechanism identified is associated with modifications
in the tubulin/microtubule system, the target of dEpoB, mutation, identified by both gene and protein sequenc-
ing, leads to a change from a hydrophobic to a polarand other antimicrotubule agents. Tubulin/microtubule
alterations include altered tubulin isotype expression residue. The mutation resides on helix 7 (H7) of-tubulin,
a region implicated in microtubule stability [23, 27, 31].and increased levels of MAP4. The increased MAP4
expression is most likely compensating for the reduced As threonine is C- branched, it introduces more bulki-
ness near to the protein backbone so that the substitu-microtubule stability induced by the acquired -tubulin
mutations. Importantly, the reduced efficacy of microtu- tion of this amino acid restricts the conformations the
main chain can adopt. In particular, it is more difficultbule-stabilizing agents in these cells was found to be
due to either decreased microtubule stability or a defect for C--branched amino acids to adopt an -helical con-
formation. We hypothesized that this mutation confersin drug binding.
Epothilones share a similar mechanism of action with a selective survival advantage to the cells in the pres-
ence of dEpoB due to decreased stability of microtu-paclitaxel [7, 8]. The effects of paclitaxel on microtubule
dynamics have been extensively studied. At low concen- bules counteracting the drug-stabilizing effects, and/
or reduced drug binding. We strongly favor the firsttrations paclitaxel strongly suppresses microtubule dy-
namics [4, 28], and at higher concentrations significantly possibility for the resistant cells harboring the A231T
mutation, as the microtubules in these cells retain theirincreases the microtubule polymer mass and induces
microtubule bundle formation [3, 28]. Studies on pacli- ability to bind paclitaxel (Figure 4). Studies from the
Cabral laboratory [32] demonstrated that mutations in ataxel-resistant cells indicate that resistance may be as-
sociated with impaired tubulin polymerization [12, 29]. leucine-rich region of -tubulin involving L215H, L217R,
and L228F were also associated with reduced microtu-All the dEpoB-resistant cell lines studied here have
greatly reduced tubulin polymer mass. In addition, the bule stability and were less sensitive to the effects of
paclitaxel. The -tubulin L228 residue lies deep in thereduction in polymer mass is inversely correlated to the
extent of dEpoB resistance. In the dEpoB30, dEpoB60, hydrophobic pocket of -tubulin on H7 and resides only
3 residues away from the A231T CEM-dEpoB mutationand to a lesser extent in the dEpoB140 cells, dEpoB
could induce polymerization of tubulin, although never also on the same helix. These authors demonstrated
that amino acid substitutions in any of these leucinesto the same overall levels as the parental cells (Figure
3). Thus, the microtubules in these cells appear to retain perturbed the assembly of microtubules. Moreover, it
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has been hypothesized that the H7 of tubulin controls dEpoB300 cells to be increasing paclitaxel resistance.
However, 2D-PAGE analysis demonstrates the loss ofthe conformation of the whole molecule [26]. Our find-
ings support and extend the observation that the H7 of one isoform of class II -tubulin, and retention of a sec-
ond, more basic isoform (Figure 5B). This is usually indic--tubulin plays an important role in microtubule stability.
Our results indicate that reduced microtubule stability ative of a change in the posttranslational modification
of class II-tubulin in these cells. Posttranslational mod-is most likely the overriding mechanism of resistance in
the dEpoB30-140 cells harboring the A231T mutation. ifications of tubulin can increase microtubule stability
(reviewed in [36–38]). We can speculate that loss of aThe demonstrated ability of tubulin in these cells to
polymerize despite their reduced intrinsic levels of poly- class II -tubulin modification may alter the interaction
of this molecule with paclitaxel; however, specific analy-merized tubulin confirms that drug-induced polymeriza-
tion can still occur, albeit to a reduced extent. In addi- sis of the modification is required to determine if this
isotype has any involvement in the heightened paclitaxeltion, the ability of paclitaxel to bind as effectively to
microtubules in the dEpoB30-140 cells as in the parental resistance.
Another likely factor contributing to the resistanceCEM cells offers further support for reduced microtubule
stability counteracting the drug effects in these cells. phenotype is the high expression of class III -tubulin
observed in the dEpoB-resistant cells. The effect ofIn addition to the A231T mutation, the dEpoB300 cells
acquired a second expressed class I -tubulin mutation, -tubulin isotype composition on microtubule assembly
and antimicrotubule drug interactions in vitro has beenQ292E, and display a reduced ability to undergo drug-
induced polymerization. Thus, a glutamine at position previously described. Tubulin dimers consisting of
-tubulin and class III -tubulin are less sensitive to the292 may be crucial for effective epothilone binding or
alternatively, destabilization of the M loop negates the suppression of microtubule dynamics by paclitaxel than
/-tubulin dimers enriched for other -tubulin isotypesstabilizing effects of the drug. This particular mutation
and amino acid substitution is of interest as it has pre- [39], and class III -tubulin-depleted microtubules un-
dergo paclitaxel-induced polymerization more readilyviously been described in EpoB-selected A549 lung can-
cer cells that are 95-fold resistant to the selecting agent than unfractionated tubulin [40]. Similar studies with
epothilones have not been reported. Studies from our[33], a level similar to the 77-fold EpoB cross-resistance
exhibited by the dEpoB300 cells. It has been implicated group and those of others have found increased expres-
sion of class III -tubulin in paclitaxel-resistant cell linesin the lateral contacts of the protofilaments and resides
on H9 near the M loop of -tubulin. It is also in close and paclitaxel-resistant ovarian tumor samples [18–20],
and downregulation of this isotype partially restoresproximity to the Thr-274 residue that forms part of the
paclitaxel/Epo binding pocket. Both glutamine and glu- paclitaxel sensitivity [41]. Therefore, the increased class
III -tubulin in the dEpoB-resistant cells studied hereintamic acid prefer to be on the surface of proteins, ex-
posed to an aqueous environment. They are frequently may be contributing to the resistance phenotype. How-
ever, it is unlikely to be the predominant mechanisminvolved in protein active or binding sites, with the polar
side chain useful for interactions with other polar or of resistance, as class III -tubulin expression did not
increase any further after the initial dEpoB30 selection,charged atoms. However, the negative charge on glu-
tamic acid means that this mutation would alter binding whereas the level of polymerized tubulin decreases con-
currently as resistance increases. In addition, gene se-interactions at this site.
Remarkably, the dEpoB300 cells display greater quencing and MS analysis reveals the relative proportion
of the Thr231 mutation over the wild-type sequence alsocross-resistance to paclitaxel than the other dEpoB-
resistant cells and to the selecting agent, dEpoB increases from the dEpoB30 to dEpoB140 cells, and
that the Glu292 mutation increases from very low levels(Table 1). While paclitaxel and epothilones appear to
share a common binding site, the exact conformation in the dEpoB140 to high levels in dEpoB300 cells (data
not shown). These findings further support that the re-and residues involved in this binding are far from clear,
especially for the epothilones. Thus, it is possible that duction in polymerized tubulin is due more to the muta-
tions than the heightened class III expression. Interest-the Q292E mutation affects binding of paclitaxel or the
ability of paclitaxel to overcome microtubule destabiliza- ingly though, class III -tubulin expression was highest
in the dEpoB30- and dEpoB300-resistant cells, andtion more so than dEpoB, indicating that these drugs
do not bind to the tubulin molecule in an identical man- these two cells lines showed the broadest hypersensi-
tivity to vinca alkaloids. Downregulation of class IIIner. The demonstration that dEpoB300 cells display a
significant reduction in paclitaxel binding on microtu- -tubulin has previously been associated with vinca al-
kaloid-resistant leukemia cells [42]. Thus, we proposebules compared to the parent and other dEpoB-resistant
cells provides direct evidence that reduced drug binding that the high class III -tubulin expression increases the
efficacy of vinca alkaloids and decreases the effectsis contributing to resistance.
We cannot exclude the possibility that other microtu- of microtubule stabilizing agents via subtle effects on
microtubule dynamics and/or drug binding, but doesbule changes are contributing to the increased resis-
tance to paclitaxel and reduced microtubule binding of not affect the intrinsic levels of polymerized tubulin.
The upregulation of MAP4 in all the dEpoB-resistantthis drug in the dEpo300 cells. The only change ob-
served exclusively in the dEpoB300 cells is the downreg- cells (Figure 4) is interesting since MAP4 is a high Mr
protein that binds to and stabilizes microtubules. Modi-ulation of class II -tubulin. Paclitaxel resistance has
previously been associated with increased expression fying the expression of MAP4 via gene overexpression or
antisense approaches leads to changes in microtubuleof class II -tubulin [34, 35]. Thus, we would not expect
the downregulation of this isotype observed in the stability and alterations in paclitaxel binding [21, 22, 43].
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In addition, increased MAP4 expression has previously binding, suggesting that this residue is crucial for ef-
fective drug binding. This study identifies novel drug/been associated with enhanced sensitivity to paclitaxel
and resistance to microtubule-destabilizing agents, target interactions, which improves our understanding
of antimicrotubule drug action and may lead to im-such as vincristine [21, 42]. Thus, it would seem counter-
intuitive to increase MAP4 expression in cells resistant proved antimicrotubule drug design.
to a microtubule-stabilizing agent such as dEpoB. The
Experimental Proceduresidentification of MAP4 in the polymerized tubulin fraction
(data not shown) indicates that MAP4 can bind to the
Cell Culture and Selection of Resistant Cells
microtubules that are present in these cells. As the in- Human T cell ALL cells, CCRF-CEM, and drug-resistant sublines
creased MAP4 expression is not resulting in the ex- were maintained in RPMI 1640 containing 10% FCS as suspension
pected increase of polymerized tubulin, we propose that cultures. CCRF-CEM cells were selected by multiple stepwise treat-
ments with increasing concentrations of dEpoB (kindly provided bythe cells may be attempting to compensate for the de-
Professor S. J. Danishefsky, Sloan-Kettering Institute for Cancercreased microtubule stability by increasing MAP4 ex-
Research, New York). Initially cells were given 4  72 hr doses ofpression. The dynamic instability within a cell is crucial
30 nM dEpoB, after which the cells were able to grow through this
for cell function and proliferation. Many cells selected treatment and designated dEpoB30. Cells were then treated 3  72
for resistance to microtubule-stabilizing drugs actually hr at 60 nM dEpoB (designated dEpoB60), 3  72 hr at 140 nM
become dependent on the drug for survival [11, 32, 33, (designated dEpoB140), and 5 72 hr at 300 nM dEpoB (designated
dEpoB300) until no decreased viability was achieved at each of the44, 45]. This indicates that the microtubule alterations
respective concentrations. The resulting cell lines have since beengiving rise to the drug resistance are so dramatic that
maintained in drug-free media.without external induction of microtubule polymeriza-
tion, cell division cannot proceed. This is strongly sup-
Growth Inhibition Assays
ported by a recent study from Barlow et al. [46] that Growth inhibition assays were performed as previously described
demonstrated that paclitaxel-dependent mutants have [47]. Briefly, cells were seeded at 15,000 cells/well in 96-well plates
a substantial depletion in their levels of polymerized in the presence or absence of the indicated drug concentrations.
Cytotoxic drugs were obtained as follows: dEpoB, Dr. S. Danishef-tubulin and require paclitaxel to stabilize the microtu-
sky, Sloan-Kettering Institute for Cancer Research, NY; vinorelbinebules for cell division to proceed. In contrast, the dEpoB-
and vinflunine, Dr. B. Hill, Pierre Fabre, France; vincristine and col-resistant cells selected here have major changes in their
chicine (Sigma); vinblastine (David Bull Laboratories, Australia);
microtubule system, but are not dependent on dEpoB doxorubicin (Pharmacia, Australia); epothilone B and paclitaxel (Cal-
for growth. It is highly feasible that the high MAP4 levels biochem, San Diego, CA). After 72 hr incubation, metabolic activity
are compensating microtubule stability sufficiently for was detected by addition of Alamar blue and spectrophotometric
analysis. Cell numbers were determined and expressed as a per-cell growth to occur in the absence of drug.
centage of control, untreated cells. Determination of IC50 values and
statistical analysis was performed as described previously [48].
Significance
MDR1 and MRP Gene Expression
PCR amplification of cDNA with specific primers for MDR1 and
Epothilones are a new class of tubulin-targeted agents MRP1, each with competitive amplification of 2-microglobulin (2M)
that, like paclitaxel, can stabilize microtubules and as a control gene, were performed as previously described [49]. The
products of triplicate PCR reactions were analyzed on polyacryl-arrest cells in mitosis. Our study has demonstrated
amide gels, and relative expression was determined by the densito-that selection of acute lymphoblastic leukemia cells
metric volume of the MDR1 or MRP1 gene product in each cell line(CCRF-CEM) for resistance to the epothilone analog,
relative to that of the control 2M gene. CEM/VCR-R cells, whichdesoxyepothilone B (dEpoB), has led to specific changes
have previously been shown to overexpress MDR1 [48] and MCF7-
in the cellular target of this drug, resulting in reduced VP16 cells, which have previously been shown to overexpress MRP1
drug efficacy. Specifically, cells selected for resis- [50], were included as positive controls.
tance to 30, 60, and 140 nM dEpoB displayed reduced
Accumulation of [3H]-Paclitaxellevels of polymerized tubulin indicative of less stable
The cellular accumulation of [3H]-paclitaxel was performed as pre-microtubules, counteracting the effects of the micro-
viously described [48]. Briefly, intracellular accumulation of pacli-tubule-stabilizing agent dEpoB. In contrast, these cells
taxel was determined by adding [3H]-paclitaxel (Moravek Biochemi-
displayed hypersensitivity to microtubule-destabi- cals Inc., Brea, CA), to 5  106 cells/1 ml in fresh growth medium
lizing agents. The reduction in polymerized tubulin and monitoring drug uptake over 1 hr. Mean incorporation was
is most likely due to an A231T mutation in class I determined for duplicate 1 ml cultures to which [3H]-paclitaxel (14.7
Ci/mmol; final concentration, 50 nM) was added. Cells were washed,-tubulin in these cells. This mutation resides within
hydrolyzed, and counted as previously described [48]. Mean incor-helix 7 of-tubulin, in a region implicated in controlling
poration of paclitaxel was determined for duplicate samples andthe conformation of the tubulin molecule. While this
expressed as pmoles of paclitaxel/mg protein. Three independent
region is also defined as part of the paclitaxel binding experiments were performed.
pocket, the A231T mutation does not inhibit drug bind-
ing. In contrast, cells selected for higher level resis- Protein Expression Analysis
Total cellular proteins (10 g) were separated by 4%–15% SDS-tance (300 nM dEpoB) display markedly reduced drug
PAGE and transferred to nitrocellulose as previously described [42].binding. These cells have acquired an additional ex-
Briefly, immunoblotting was performed using mAbs to class Ipressed mutation in class I -tubulin, Q292E, near the
-tubulin (kind gift of Dr. Luduena, University of Texas, San Antonio,M loop of -tubulin, a region implicated in the lateral
TX), class II -tubulin, class III -tubulin (Sigma), and MAP4 (Trans-
contacts of tubulin and microtubule stability. The tu- duction Labs). Following incubation with a sheep anti-mouse horse-
bulin in these cells fails to undergo drug-induced poly- radish-peroxidase-linked IgG antibody, membranes were devel-
oped using Supersignal (Pierce, Rockford, IL). Ponceau S stainingmerization and displays ineffective [3H]-paclitaxel
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and a pAb to total actin (Sigma) were used to control for loading. a sample plate with 1 l of matrix (-cyano-4-hydroxycinnamic acid,
8 mg/ml in 50% v/v AcN, 1% v/v TFA). Matrix-assisted laser desorp-Protein quantitation was performed on a Phosphorimager (Bio-Rad,
Australia) and protein expression determined by dividing the densi- tion ionization-time of flight (MALDI-TOF) mass spectrometry acqui-
sition was performed on a TofSpec 2E mass spectrometer (Micro-tometric value of the test protein by that of the control protein (actin).
Statistical differences between the CEM cells and dEpoB-resistant mass, Manchester, UK) set to reflectron mode. Known trypsin
autocleavage peptide masses (842.51 Da; 2211.10 Da) were usedcells were assessed using analysis of variance. All experiments were
performed at least four times. for a 2-point internal calibration for each spectrum. Peptide masses
were searched against SwissProt/TrEMBL protein databases using
the PeptIdent tool on ExPASy (http://tw.expasy.org/tools/peptident.Measurement of Polymerized Tubulin
html) for protein identification.Soluble (cytosolic) and polymerized (cytoskeletal) fractions of tu-
bulin were separated as previously described [42]. Briefly, 2  106
cells were suspended in 100 l hypotonic buffer (1 mM MgCl2, 2 mM ESI-TOF Tandem Mass Spectrometry
Upon analysis of MALDI-TOF mass spectra, class I -tubulin peptidesEGTA, 0.5% NP-40, 2 mM phenylmethylsulfonyl fluoride, 10 l/ml
protease inhibitor cocktail [Sigma], 20 mM Tris-HCl [pH 6.8]), incu- differing in mass between the parental CEM cells and drug-resistant
cells were selected for amino acid sequencing by ESI-TOF MS/MS.bated at 37	C for 5 min in the dark, and an additional 100 l buffer
added. Polymerized tubulin was collected in the pellet following After in-gel trypsin digestion, the peptides were purified using a porous
R2 resin column [56]. The sample was then analyzed by ESI-TOF MS/centrifugation at 18,000 g for 10 min. Protein fractions were sepa-
rated by SDS-PAGE and levels of tubulin determined by immu- MS using a Micromass Q-TOF MS and data manually acquired using
borosilicate capillaries for nanospray acquisition. Data was acquirednoblotting and detection using a mAb to -tubulin (Sigma). In addi-
tion, to assess the ability of dEpoB to induce tubulin polymerization over the m/z range 400–1800 Da to select peptides for MS/MS analysis.
After peptides were selected, the MS was switched to MS/MS modein the resistant cell lines, 4g/ml dEpoB was added to the hypotonic
lysis buffer and the assay performed as above. All experiments were and data collected over the m/z range 50–2000 Da with variable colli-
sion energy settings. The peptide sequences were compared to theperformed at least three times.
parental CEM cells and the published sequences [51, 52].
[3H]-Paclitaxel Binding Assay
Midlog phase cells were suspended at a final concentration of 5  Tubulin Mutation Modeling
Computer models of the locations of mutations identified within106 cells/ml in fresh RMPI/10% FCS. [3H]-paclitaxel (14.7 Ci/mmol;
final concentration, 50 nM) was added to duplicate 1 ml cultures -tubulin of dEpoB-resistant cells were prepared using the ViewerLite
program from Accelerys. Coordinates for wild-type -tubulin were ob-and incubated at 37	C for 1 hr. Cells were pelleted at 2000  g for
1 min and washed thoroughly four times with warm (37	C) PBS. tained from the Protein Data Bank (PDB accession code: 1JFF). Mu-
tated proteins were created using the MUTATE command withinSoluble and polymerized fractions of tubulin were then separated
as described above [42]. Protein concentration in each fraction was SWISS PDB viewer.
determined using the BCA assay (Pierce). The remaining sample
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